Low-Dose Radiation for Knee Osteoarthritis: New Trial Shows Pain Relief & Improved Mobility

For millions living with the daily ache of osteoarthritis, particularly in the knees, a new approach to pain management is gaining traction. A recent randomized, placebo-controlled clinical trial originating in Korea suggests that low-dose radiation therapy could offer a safe and effective alternative for those seeking relief, bridging the gap between medication and more invasive surgical options. The findings, initially presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting, build on decades of experience with this treatment in parts of Europe, but represent a significant step forward in establishing rigorous scientific evidence.

Understanding Osteoarthritis and Current Treatment Options

Osteoarthritis, the most common form of arthritis, affects an estimated 32.5 million adults in the United States alone. The Centers for Disease Control and Prevention (CDC) defines the condition as a breakdown of cartilage – the protective tissue cushioning the ends of bones – leading to pain, stiffness, and reduced mobility. While there’s no cure, treatment typically begins with lifestyle adjustments like weight management and exercise, alongside pain-relief medications. When these measures prove insufficient, patients often face a difficult choice: continue managing pain with potentially problematic medications, or undergo joint replacement surgery.

Here’s where low-dose radiation therapy enters the conversation. The treatment isn’t new; it’s been used for years in countries like Germany and Spain. However, as Dr. Byoung Hyuck Kim, principal investigator of the Korean trial and an assistant professor of radiation oncology at Seoul National University College of Medicine, Boramae Medical Center, points out, a lack of robust, placebo-controlled studies has limited its widespread adoption elsewhere. “There’s a clinical demand for moderate interventions between weak pain medications and aggressive surgery, and we think radiation may be a suitable option for those patients especially when drugs and injections are poorly tolerated,” he stated.

The Korean Trial: Design and Key Findings

The study, involving 114 participants with mild to moderate knee osteoarthritis, was designed to address the evidence gap. Participants were randomly assigned to one of three groups: a very low dose of radiation (0.3 Gy), a low dose (3 Gy), or a control group receiving a sham treatment – meaning they underwent the same procedure without actually receiving radiation. This “sham” control is crucial, as placebo effects are notoriously strong in osteoarthritis trials. Each participant received six treatment sessions over a period of time, and were monitored for four months.

Researchers deliberately restricted the use of stronger pain relievers, allowing only acetaminophen as needed, to ensure any observed improvements could be directly attributed to the radiation therapy itself. Effectiveness was measured using internationally recognized standards, defining a “responder” as someone experiencing meaningful improvement in at least two out of three areas: pain, physical function, and overall condition.

The results were encouraging. After four months, 70% of patients in the 3 Gy group met the criteria for a responder, compared to 42% in the placebo group (p=0.014). The 0.3 Gy group showed improvement, but it wasn’t statistically significant compared to the placebo group (58.3% improved, p=0.157). This suggests the 3 Gy dose was the key driver of relief beyond the placebo effect. Significant improvements in pain, stiffness, and physical function were reported more often in the 3 Gy group (56.8%) than in the placebo group (30.6%, p=0.024).

Addressing the Placebo Effect and Prior Research

Dr. Kim emphasized two critical aspects of this trial that differentiate it from previous research. First, the sham-controlled design effectively ruled out placebo effects. Second, limiting the use of stronger analgesics – like NSAIDs or opioids – allowed researchers to more clearly attribute any differences between groups to the radiation therapy itself. As reported by Penn Medicine, previous studies often included these stronger pain relievers, potentially masking the true effects of the radiation.

Interestingly, the placebo response rate – around 40% – was substantial, aligning with rates seen in other osteoarthritis trials involving injections or medications. Dr. Kim noted this underscores the importance of placebo-controlled designs in osteoarthritis research, suggesting a need for further investigation into the psychological and physiological factors contributing to these responses.

Safety and Dosage Considerations

A significant reassurance from the study is the absence of radiation-related side effects. The radiation dose used was less than 5% of what is typically used in cancer therapy, and the treatment targeted joints positioned away from vital organs, minimizing potential risks. “There is a misconception that medicinal, or therapeutic, radiation is always delivered in high doses,” Dr. Kim explained. “But for osteoarthritis, the doses are only a small fraction of what we use for cancer, and the treatment targets joints that are positioned away from vital organs, which lowers the likelihood of side effects.”

Who Might Benefit and What’s Next?

Dr. Kim believes low-dose radiation therapy may be particularly well-suited for patients with underlying inflammation and relatively preserved joint structure. “For severe osteoarthritis, where the joint is physically destroyed and cartilage is already gone, radiation will not regenerate tissue,” he clarified. “But for people with mild to moderate disease, this approach could delay the need for joint replacement.” He stresses that this treatment should be considered as part of a shared decision-making process, alongside established approaches like weight loss, physiotherapy, and medication.

The research team is currently completing a 12-month follow-up to assess the long-term durability of the benefits and to correlate symptom relief with imaging-based measures of joint structure. Future plans include larger, more pragmatic trials to evaluate outcomes in specific subgroups and to conduct health-economic analyses comparing low-dose radiation with injections and medication regimens. As highlighted by the Cleveland Clinic in a recent case study, this treatment is showing promise even in elderly patients.

This research represents a promising development in the management of osteoarthritis, offering a potential new option for those seeking relief from chronic joint pain. However, it’s crucial to remember that this is an evolving field, and further research is needed to fully understand the long-term benefits and optimal use of low-dose radiation therapy.